Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.31 |
| ▸ | SPR | P35270 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 3/20 | 0.30 |
| ▸ | HTR7 | P34969 | 3/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17049029 | 0.89 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL17097651 | 0.89 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL17110308 | 0.85 | ALDH1A1 (0.36) | ALDH1A1MAPTHSD11B1MMP13 | |
| SCHEMBL17097867 | 0.83 | ALDH1A1 (0.34) | ALDH1A1MAPTHSD11B1SMN1; SMN2 | |
| SCHEMBL17097866 | 0.83 | ALDH1A1 (0.34) | ALDH1A1MAPTHSD11B1SMN1; SMN2 | |
| SCHEMBL17110303 | 0.83 | ALDH1A1 (0.34) | ALDH1A1MAPTHSD11B1MMP13KCNH2 | |
| SCHEMBL17110285 | 0.82 | ALDH1A1 (0.32) | ALDH1A1MAPTHSD11B1 | |
| SCHEMBL17110316 | 0.81 | ALDH1A1 (0.34) | ALDH1A1MAPTHSD11B1SMN1; SMN2 | |
| SCHEMBL17110279 | 0.76 | ALDH1A1 (0.41) | ALDH1A1MAPTHSD11B1SMN1; SMN2 | |
| SCHEMBL17098971 | 0.76 | HSD11B1 (0.33) | HSD11B1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365522-B2 | Pyrazole amide derivative | AMGEN INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150266824-A1 | Pyrazole Amide Derivative | TEIJIN LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266824-A1 | Pyrazole Amide Derivative | RORC, RORB, RORA | ALDH1A1 923/4885MAPT 3584/4885HSD11B1 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.